Wall Street brokerages expect Davita Inc (NYSE:DVA) to announce $3.83 billion in sales for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Davita’s earnings, with estimates ranging from $3.79 billion to $3.88 billion. Davita posted sales of $3.72 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 3%. The company is expected to issue its next quarterly earnings report on Monday, August 14th.

According to Zacks, analysts expect that Davita will report full-year sales of $3.83 billion for the current financial year, with estimates ranging from $15.06 billion to $15.47 billion. For the next year, analysts expect that the company will report sales of $15.93 billion per share, with estimates ranging from $15.63 billion to $16.32 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Davita.

Davita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by $0.03. The firm had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.69 billion. Davita had a return on equity of 16.16% and a net margin of 4.92%.

Several research analysts recently weighed in on DVA shares. Zacks Investment Research cut Davita from a “hold” rating to a “sell” rating in a research note on Tuesday, January 31st. Royal Bank of Canada reaffirmed a “hold” rating and set a $62.00 target price on shares of Davita in a research note on Friday, February 17th. TheStreet raised Davita from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Goldman Sachs Group Inc reaffirmed a “sell” rating and set a $62.00 target price on shares of Davita in a research note on Thursday. Finally, Jefferies Group LLC set a $70.00 target price on Davita and gave the company a “buy” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $69.50.

In related news, Director William L. Roper sold 12,994 shares of the stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $65.89, for a total value of $856,174.66. Following the completion of the transaction, the director now owns 45,277 shares in the company, valued at approximately $2,983,301.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Javier Rodriguez sold 1,294 shares of the stock in a transaction on Monday, May 15th. The shares were sold at an average price of $66.21, for a total value of $85,675.74. Following the completion of the transaction, the chief executive officer now owns 99,111 shares of the company’s stock, valued at approximately $6,562,139.31. The disclosure for this sale can be found here. Insiders sold a total of 22,702 shares of company stock valued at $1,495,492 in the last quarter. 2.10% of the stock is currently owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in DVA. Norges Bank bought a new position in Davita during the fourth quarter worth $140,920,000. Assenagon Asset Management S.A. bought a new position in Davita during the fourth quarter worth $5,190,000. Jarislowsky Fraser Ltd raised its position in Davita by 4.0% in the fourth quarter. Jarislowsky Fraser Ltd now owns 1,452,413 shares of the company’s stock worth $93,244,000 after buying an additional 55,670 shares during the period. Cigna Investments Inc. New bought a new position in Davita during the fourth quarter worth $381,000. Finally, SRS Capital Advisors Inc. bought a new position in Davita during the fourth quarter worth $118,000. Institutional investors and hedge funds own 85.31% of the company’s stock.

Davita (NYSE:DVA) opened at 64.75 on Friday. The firm has a market cap of $12.60 billion, a P/E ratio of 10.63 and a beta of 1.02. Davita has a 1-year low of $54.50 and a 1-year high of $78.77. The stock’s 50 day moving average price is $66.78 and its 200 day moving average price is $65.57.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/05/28/brokerages-anticipate-davita-inc-dva-will-announce-quarterly-sales-of-3-83-billion.html.

Davita Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

12 Month Chart for NYSE:DVA

Get a free copy of the Zacks research report on Davita (DVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Davita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita Inc and related companies with MarketBeat.com's FREE daily email newsletter.